Shidlovski/iStock via Getty Images
Viatris (NASDAQ:VTRS) shares fell in the premarket on Friday after the company announced that its experimental therapy for blepharitis, an inflammatory condition of the eyelids, did not reach the main goal in a late-stage trial.
Citing data from its MR-139 3001 Phase 3 Study, the Pfizer (PFE) spinoff said that the ophthalmic ointment named pimecrolimus 0.3% (MR-139) did not reach the trial’s primary endpoint related to complete resolution of debris over six weeks.
The 477-patient placebo-controlled trial evaluated MR-139, self-administered to the eyelids, with a twice-daily dosing regimen over 12 weeks.
“Given that the study did not meet its objective for patients suffering from blepharitis, we are evaluating the appropriate next steps for the Phase 3 program,” Viatris’ (NASDAQ:VTRS) R&D chief Philippe Martin remarked.
Changing the planned additional Phase 3 study for the drug is also among those plans, he added.
More on Viatris
- Viatris: A Contrarian Bet With Virtually No Downside
- Viatris: The Problem With The Business Model
- Viatris Inc. (VTRS) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
- ViiV expands license to produce generic Apretude in low-income countries
- J&J wins appeals court ruling against Teva and Viatris in patent dispute over neuro drug